Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
osimertinib (428) 428
oncology (249) 249
mutation (180) 180
index medicus (176) 176
gefitinib (153) 153
lung cancer (149) 149
humans (133) 133
chemotherapy (128) 128
acquired-resistance (116) 116
open-label (107) 107
non-small cell lung cancer (106) 106
lung cancer, non-small cell (104) 104
epidermal growth factor (103) 103
azd9291 (101) 101
respiratory system (99) 99
lung neoplasms - drug therapy (92) 92
resistance (90) 90
cell lung-cancer (89) 89
nsclc (87) 87
t790m (87) 87
cancer (84) 84
carcinoma, non-small-cell lung - drug therapy (83) 83
erbb receptors - genetics (83) 83
egfr (82) 82
erlotinib (81) 81
adenocarcinoma (80) 80
tyrosine (79) 79
lung neoplasms - genetics (78) 78
1st-line treatment (74) 74
afatinib (74) 74
respiratory tract diseases (73) 73
tyrosine kinase inhibitors (71) 71
female (70) 70
carcinoma, non-small-cell lung - genetics (63) 63
patients (63) 63
epidermal growth factor receptor (61) 61
protein kinase inhibitors - therapeutic use (61) 61
genetic aspects (59) 59
non-small cell lung carcinoma (58) 58
piperazines - therapeutic use (54) 54
cancer therapies (53) 53
care and treatment (53) 53
epidermal growth factor receptors (53) 53
t790m mutation (53) 53
development and progression (52) 52
lung neoplasms - pathology (52) 52
male (52) 52
metastasis (52) 52
antineoplastic agents - therapeutic use (51) 51
mutations (50) 50
kinases (48) 48
aged (47) 47
egfr mutation (47) 47
middle aged (47) 47
neoplasms. tumors. oncology. including cancer and carcinogens (47) 47
analysis (46) 46
biopsy (43) 43
inhibitors (43) 43
carcinoma, non-small-cell lung - pathology (42) 42
therapy (42) 42
case report (40) 40
phase-iii (39) 39
multicenter (38) 38
pharmacology & pharmacy (38) 38
protein-tyrosine kinase (34) 34
tyrosine kinase inhibitor (33) 33
protein kinase inhibitors - pharmacology (32) 32
erbb receptors - antagonists & inhibitors (31) 31
brain metastases (30) 30
research (30) 30
tumors (30) 30
drug therapy (29) 29
growth-factor receptor (29) 29
health aspects (29) 29
adult (28) 28
antineoplastic agents - pharmacology (28) 28
drug resistance, neoplasm - genetics (28) 28
piperazines - pharmacology (28) 28
treatment outcome (28) 28
lung cancer, small cell (27) 27
mechanisms (27) 27
plasma (26) 26
gene mutations (25) 25
non-small-cell lung cancer (25) 25
survival (25) 25
crizotinib (24) 24
acquired resistance (23) 23
clinical trials (23) 23
drug resistance (22) 22
liquid biopsy (22) 22
original (22) 22
animals (21) 21
apoptosis (21) 21
disease progression (21) 21
biochemistry & molecular biology (20) 20
egfr mutations (20) 20
egfr-tki (20) 20
metastases (20) 20
review (20) 20
tki (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phase 2 study evaluating the MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiological progression: the MELROSE trial
by J, Bennouna and N, Girard and Audigier-Valette, C and A, le Thuaut and R, Gervais and P, Masson and M, Marcq and O, Molinier and A, Cortot and D, Debieuvre and J, Cadranel and H, Lena and Moro-Sibilot, D and C, Chouaid and B, Mennecier and T, Urban and C, Sagan and L, Perrier and F, Barlesi and MG, Denis
Clinical Lung Cancer, ISSN 1525-7304, 10/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy
by Wang, Xiaofei and Zhou, Ling and Yin, Jiani C and Wu, Xue and Shao, Yang W and Gao, Beili
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2019, Volume 14, Issue 5, pp. e85 - e88
T790M | OSIMERTINIB | C797S | ONCOLOGY | RESPIRATORY SYSTEM | AZD9291
Journal Article
Details down arrow
3. Full Text Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
by Schoenfeld, A.J and Arbour, K.C and Rizvi, H and Iqbal, A.N and Gadgeel, S.M and Girshman, J and Kris, M.G and Riely, G.J and Yu, H.A and Hellmann, M.D
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 839 - 844
Background: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth... 
TKI | irAE | PD-1 | EGFR | osimertinib | ONCOLOGY | SAFETY | CLINICAL ACTIVITY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers
by Offin, Michael and Rizvi, Hira and Tenet, Megan and Ni, Andy and Sanchez-Vega, Francisco and Li, Bob T and Drilon, Alexander and Kris, Mark G and Rudin, Charles M and Schultz, Nikolaus and Arcila, Maria E and Ladanyi, Marc and Riely, Gregory J and Yu, Helena and Hellmann, Matthew D
Clinical Cancer Research, ISSN 1078-0432, 02/2019, Volume 25, Issue 3, pp. 1063 - 1069
Purpose: Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint blockade (ICB). The impact of TMB on outcomes with targeted therapies has... 
CTLA-4 BLOCKADE | FACTOR-RECEPTOR GENE | GEFITINIB | CARBOPLATIN | OSIMERTINIB | ONCOLOGY | LANDSCAPE | ADENOCARCINOMA | SENSITIVITY | NEOANTIGENS | PACLITAXEL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?
by Hata, Akito and Katakami, Nobuyuki and Kaji, Reiko and Yokoyama, Toshihide and Kaneda, Toshihiko and Tamiya, Motohiro and Inoue, Takako and Kimura, Hiromi and Yano, Yukihiro and Tamura, Daisuke and Morita, Satoshi and Negoro, Shunichi and HANSHIN Oncology Group
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 78, pp. 34765 - 34771
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are markedly effective for T790M-positive patients. To confer their... 
Osimertinib | T790M | Afatinib | Rebiopsy | Bevacizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France)
by Heeke, Simon and Benzaquen, Jonathan and Hofman, Véronique and Ilié, Marius and Allegra, Maryline and Long-Mira, Elodie and Lassalle, Sandra and Tanga, Virginie and Salacroup, Carole and Bonnetaud, Christelle and Fayada, Julien and Gazoppi, Loïc and Ribeyre, Lydia and Castelnau, Olivier and Garnier, Georges and Cattet, Florian and Nanni, Isabelle and de Fraipont, Florence and Cohen, Charlotte and Berthet, Jean-Philippe and Leroy, Sylvie and Poudenx, Michel and Marquette, Charles Hugo and Denis, Marc G and Barlesi, Fabrice and Hofman, Paul
Clinical lung cancer, ISSN 1525-7304, 08/2019
The introduction of liquid biopsy using PCR-based assays into routine practice has had a strong impact on the treatment of EGFR-mutated lung adenocarcinoma and... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases
by Tsuchiya, Kazuo and Karayama, Masato and Yasui, Hideki and Hozumi, Hironao and Suzuki, Yuzo and Furuhashi, Kazuki and Enomoto, Noriyuki and Fujisawa, Tomoyuki and Nakamura, Yutaro and Inui, Naoki and Suda, Takafumi
Internal Medicine, ISSN 0918-2918, 2019
A 53-year-old man with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 19 deletion received erlotinib. After 12 months of... 
lung cancer | bevacizumab | leptomeningeal metastases | EGFR | osimertinib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Acquired &ITEGFR&IT L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib
by Liu, YT and Li, Y and Ou, QX and Wu, X and Wang, XN and Shao, YW and Ying, JM
LUNG CANCER, ISSN 0169-5002, 04/2018, Volume 118, pp. 1 - 5
Objectives: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising targeted therapies for EGFR-mutated non-small-cell lung... 
Resistance | Afatinib | NSCLC | ONCOLOGY | RESPIRATORY SYSTEM | Osimertinib | L718V | EGFR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Genetic Profiling of Non‐Small Cell Lung Cancer at Development of Resistance to First‐ or Second‐Generation EGFR‐TKIs by CAPP‐Seq Analysis of Circulating Tumor DNA
by Otsubo, Kohei and Sakai, Kazuko and Takeshita, Masafumi and Harada, Daijiro and Azuma, Koichi and Ota, Keiichi and Akamatsu, Hiroaki and Goto, Koichi and Horiike, Atsushi and Kurata, Takayasu and Nakagaki, Noriaki and Nosaki, Kaname and Iwama, Eiji and Nakanishi, Yoichi and Nishio, Kazuto and Okamoto, Isamu
The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. 1022 - 1026
Patients with non‐small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) eventually acquire... 
ACQUIRED-RESISTANCE | AMPLIFICATION | OSIMERTINIB | THERAPY | MUTATIONS | ONCOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice?
by Bersanelli, Melissa and Gelsomino, Francesco and Buti, Sebastiano and Fiorentino, Michelangelo and Tiseo, Marcello
Translational Cancer Research, ISSN 2218-676X, 2017, Volume 6, Issue S1, pp. S61 - S64
ONCOLOGY | AZD9291 | OSIMERTINIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors
by Zhou, Zhen and Zhao, Yi and Shen, Shengping and Gu, Linping and Niu, Xiaomin and Xu, Yunhua and Zhang, Tengfei and Xiang, Jianxing and Mao, Xinru and Lu, Shun
Journal of Thoracic Oncology, ISSN 1556-0864, 2019, Volume 14, Issue 8, pp. E157 - E159
T790M | OSIMERTINIB | C797S | ONCOLOGY | RESPIRATORY SYSTEM
Journal Article
Details down arrow
12. Osimertinib - a new treatment option for patients with EGFR mutation T790M
by Svatoň, Martin and Hrdá, Kristýna and Pešek, Miloš
Onkologie (Czech Republic), ISSN 1802-4475, 2017, Volume 11, Issue 2, pp. 72 - 77
Osimertinib | T790M | AURA3 | EGFR
Journal Article
Details down arrow
13. Full Text Extending the curve: Survival of EGFR-mutated lung cancer patients in the 21st century
by Barrón, Feliciano and Zatarain-Barrón, Zyanya Lucia and Cardona, Andrés F and Arrieta, Oscar
Journal of Thoracic Disease, ISSN 2072-1439, 03/2018, Volume 10, Issue 3, pp. 1265 - 1268
TRIAL | THERAPIES | OSIMERTINIB | RESPIRATORY SYSTEM
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with
by Papadimitrakopoulou, Vassiliki A
Lung Cancer Management, ISSN 1758-1966, 12/2016, Volume 5, Issue 4, pp. 159 - 162
Dr Papadimitrakopoulou is the Jay and Lori Eisenberg Distinguished Professor of Medicine and Chief of the section of Thoracic Medical Oncology in the... 
NSCLC | osimertinib | T790M
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
by Jimbo, Takeshi and Hatanaka, Mana and Komatsu, Takahiro and Taira, Tomoe and Kumazawa, Kentaro and Maeda, Naoyuki and Suzuki, Takashi and Ota, Masahiro and Haginoya, Noriyasu and Isoyama, Takeshi and Fujiwara, Kosaku
Oncotarget, ISSN 1949-2553, 08/2019, Volume 10, Issue 50, p. 5152
The AXL receptor tyrosine kinase is involved in signal transduction in malignant cells. Recent studies have shown that the AXL upregulation underlies epidermal... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
by Goss, G and Tsai, C -M and Shepherd, F A and Ahn, M -J and Bazhenova, L and Crinò, L and de Marinis, F and Felip, E and Morabito, A and Hodge, R and Cantarini, M and Johnson, M and Mitsudomi, T and Jänne, P A and Yang, J C -H
Annals of Oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 687 - 693
Abstract Background Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic... 
CNS | Osimertinib | Brain metastases | NSCLC | GEFITINIB | brain metastases | METASTASES | WHOLE-BRAIN RADIOTHERAPY | PHASE-2 | CELL LUNG-CANCER | THERAPY | STEREOTACTIC RADIOSURGERY | ONCOLOGY | osimertinib | RESISTANCE | INHIBITORS | ERLOTINIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
by Watanabe, Hiromi and Ichihara, Eiki and Kano, Hirohisa and Ninomiya, Kiichiro and Tanimoto, Mitsune and Kiura, Katsuyuki
Internal Medicine, ISSN 0918-2918, 2017
We herein report a case of congestive heart failure which developed during osimertinib treatment. A 78-year-old woman presented with mild exertional dyspnea... 
lung cancer | heart failure | osimertinib | T790M
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Immunotherapy in tyrosine kinase inhibitor-naive advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer
by Tay, RY and Ackermann, CJ and Califano, R
TRANSLATIONAL LUNG CANCER RESEARCH, ISSN 2218-6751, 12/2018, Volume 7, Issue Suppl 4, pp. S377 - S380
OSIMERTINIB | ONCOLOGY | NIVOLUMAB | RESPIRATORY SYSTEM | DOCETAXEL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
by La Monica, Silvia and Cretella, Daniele and Bonelli, Mara and Fumarola, Claudia and Cavazzoni, Andrea and Digiacomo, Graziana and Flammini, Lisa and Barocelli, Elisabetta and Minari, Roberta and Naldi, Nadia and Petronini, Pier Giorgio and Tiseo, Marcello and Alfieri, Roberta
Journal of Experimental and Clinical Cancer Research, ISSN 1756-9966, 12/2017, Volume 36, Issue 1
Osimertinib | T-DM1 | NSCLC | EGFR | TKI-resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L)
by Akamatsu, Hiroaki and Teraoka, Shunsuke and Morita, Satoshi and Katakami, Nobuyuki and Tachihara, Motoko and Daga, Haruko and Yamamoto, Nobuyuki and Nakagawa, Kazuhiko
Clinical Lung Cancer, ISSN 1525-7304, 07/2019, Volume 20, Issue 4, pp. e492 - e494
Osimertinib is a standard treatment for ( )-mutated, -positive patients with progression during EGFR-tyrosine kinase inhibitor (TKI) therapy. Osimertinib, a... 
EGFR mutation | Osimertinib | Bevacizumab | CELL LUNG-CANCER | MULTICENTER | ONCOLOGY | ERLOTINIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.